Multi-layer dynamic regulation system for producing 2'-fucosyllactose and use thereof
Through a multi-layer dynamic regulation system, the expression of 2'-fucosyl lactose and central carbon metabolism-related genes is dynamically regulated, which solves the problems of cell metabolic stress and by-product accumulation under static regulation, and significantly improves the synthesis of 2'-FL Efficiency and yield enable more efficient product synthesis.
Patent Information
- Application Number
- PCT/CN2023/140291
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-06-09
- Filing Date
- 2023-12-20
- Publication Date
- 2024-12-12
AI Technical Summary
The existing 2'-fucosyl lactose microbial cell factories have problems with cell metabolic pressure and by-product accumulation under static regulation, which limits the efficiency of product synthesis.
A multi-layer dynamic regulatory system was designed to dynamically regulate the 2'-fucosyl lactose synthesis-related genes and central carbon metabolism-related genes through constitutively expressed crRNA targeting 2'-fucosyl lactose synthesis-related genes, combining the regulator LsrR and the defective nuclease dCas12a. Gene expression reduces metabolic overflow and by-product accumulation, and coordinates cell growth and product synthesis.
The efficiency of 2'-FL de novo synthesis was effectively improved, and the yield increased from 9.1 g/L to 18.4 g/L, without the need for additional inducers, simplifying the construction and application prospects of genetically engineered strains.
Smart Images

Figure CN2023140291_12122024_PF_FP_ABST
Abstract
Description
A multi-layer dynamic control system for producing 2-fucosyllactose and its application Technical Field
[0001] The invention relates to a multi-layer dynamic control system for producing 2'-fucosyllactose and application thereof, belonging to the field of biotechnology. Background Art
[0002] Human milk oligosaccharides (HMOs) are a unique class of complex carbohydrates found in breast milk. They can regulate the balance of intestinal flora by stimulating the growth of beneficial intestinal bacteria in newborns, such as Bifidobacterium and Lactobacillus, and thus play a crucial role in regulating the neonatal immune system after birth. Furthermore, HMOs can inhibit the adhesion of pathogens to glycans on the surface of epithelial cells, thereby reducing the virulence of some pathogens. HMOs have a variety of core monosaccharide structural units. Based on the different spatial configurations, glycosyl sequences, and chain lengths of the monosaccharide structural units, HMOs can be divided into three categories: neutral fucosyllactose, acidic sialyllactose, and neutral non-fucosylated lactose. Among the numerous HMOs oligosaccharide structures, approximately 50% of HMOs are fucosylated, and 2'-fucosyllactose (2'-FL) is currently the most promising type of fucosyllactose. Because of its physiological functions such as inhibiting pathogen infection, regulating intestinal flora, and enhancing immunity, it has been approved by multiple authoritative food safety risk assessment agencies at home and abroad as a nutritional additive in infant formula and special needs foods.
[0003] Among the 2'-FL microbial cell factories currently constructed, most focus on statically controlled pathway reconfiguration and multi-module assembly optimization. For example, Katja et al. engineered a de novo 2'-FL biosynthesis pathway in Escherichia coli using sucrose as the sole carbon source. By introducing the UDP-galactosyltransferase GalTpm1141, they enabled endogenous synthesis of the substrate lactose within the cell. Overexpression of Fkp and AfcB enhanced the supply of the precursor GDP-L-fucose. Furthermore, the sugar transporter TPYb was introduced to promote extracellular export of 2'-FL. After 84 hours of fermentation, 2'-FL production reached 60 g / L. Huang et al. systematically screened α1,2-fucosyltransferases from different sources, knocked out competing pathways, and improved cofactor supply through static control strategies, generating strains that efficiently synthesized 2'-FL and 3-fucosyllactose (3-FL) in E. coli. Compared with static regulation, dynamic regulation strategies can eliminate the accumulation of toxic intermediate metabolites, allowing cell growth and product synthesis to reach a relative equilibrium, thereby effectively improving product synthesis efficiency. Therefore, dynamic regulation strategies have also been used to design and construct microbial cell factories for efficient 2'-FL synthesis. For example, Deng et al. developed an in vivo bifunctional gene expression control circuit in Bacillus subtilis based on a thrombin-binding aptamer to dynamically regulate 2'-FL synthesis. This circuit upregulated the expression of key genes fkp and futC in the 2'-FL biosynthesis pathway and downregulated the expression of purR, increasing 2'-FL production from 24.7 mg / L to 674 mg / L. Yu et al. designed and developed a temperature-responsive multi-module sequential regulation system for sequentially controlling the 2'-FL synthesis module and the competition module in B. subtilis, establishing a dual-stage fermentation technology for 2'-FL synthesis, increasing 2'-FL production to 28.2 g / L.
[0004] With the rapid development of synthetic biology tools and the widespread application of dynamic control strategies, "layered" autonomous strategies based on multiple metabolic flux nodes and "multi-input" autonomous strategies that sense multiple signal stimuli and respond to one or more metabolic flux nodes have been used to design, construct, and characterize more complex genetic control circuits to regulate metabolic flux in synthetic pathways. A key issue in the design of multi-layer gene circuits is the development of orthogonal control systems with high specificity and low noise. This can be achieved by optimizing the range or threshold of the regulatory elements' response to substrate molecules, reducing the interference of intermediate metabolites of each component on the signal, and improving the stability of the gene circuit. Among them, multi-layer dynamic control strategies based on quorum sensing (QS) systems can autonomously regulate the metabolic flux of multiple nodes in a manner independent of the synthetic pathway. For example, researchers have developed a two-layer regulatory system that combines two QS orthogonal systems, LuxI / LuxR and Esa, which can achieve simultaneous upregulation and downregulation of genes and has been successfully applied to the biosynthesis of capsaicin and salicylic acid.
[0005] Dynamic regulation strategies can effectively alleviate the problems of cell growth arrest and metabolic imbalance caused by static regulation, providing a new and effective means to maximize the yield of target product synthesis. In recent years, multi-layer dynamic regulation strategies have shown great potential in addressing the limited regulatory scope of dynamic response elements and the dual regulation of multiple genes, and have been applied to the metabolic regulation of various synthetic products. However, a two-layer gene regulatory circuit constructed by two exogenous QS systems can impose a metabolic burden on cells, and crosstalk between different QS systems can affect the fine regulation of metabolic nodes. Furthermore, the limited number and variety of biosensors for specific compounds in the response pathways restricts their widespread application in microorganisms. Furthermore, most current CRISPR-dCas9 programmable circuits are driven by the inducers arabinose and tetracycline, which has certain limitations for industrial-scale application. Therefore, designing a CRISPR-dCas12a regulatory system coupled to cell growth is promising for achieving multi-layer dynamic dual regulation of genes.
[0006] Summary of the Invention
[0007] In order to alleviate the cellular metabolic pressure caused by the competitive consumption of intracellular nutrients by central carbon metabolism and the 2'-FL de novo synthesis pathway, the present invention provides a multi-layer dynamic regulatory system, which is used to dynamically downregulate the expression levels of the central carbon metabolism pathway gene pfkA and upregulate the expression levels of the 2'-FL de novo synthesis pathway genes manB, manC, gmd, fcl, and rcsA. Without the need for additional inducers, the metabolic flow of cell growth and product synthesis can be dynamically coordinated, reducing the accumulation of the byproduct acetic acid caused by metabolic overflow, thereby maximizing the efficiency of 2'-FL de novo synthesis.
[0008] The first object of the present invention is to provide a multi-layer dynamic regulatory system for producing 2′-fucosyllactose, the multi-layer dynamic regulatory system comprising: a constitutively expressed first crRNA targeting a gene related to 2′-fucosyllactose synthesis, a constitutively expressed second crRNA targeting a gene related to central carbon metabolism, a constitutively expressed regulatory factor LsrR, an inducible promoter P lsrA regulated defective nuclease dCas12a;
[0009] in,
[0010] The multi-layer dynamic regulatory system upregulates the expression of genes related to 2′-fucosyllactose synthesis and downregulates the expression of genes related to central carbon metabolism;
[0011] The 2′-fucosyllactose synthesis-related genes include one or more of the following: phosphomannose mutase gene manB, mannose-1-phosphate guanylyltransferase gene manC, GDP-mannose 4,6-dehydratase gene gmd, GDP-L-fucose synthase gene fcl, and transcriptional regulatory protein gene rcsA;
[0012] The central carbon metabolism-related genes include the 6-phosphofructokinase gene pfkA.
[0013] Furthermore, the first crRNA and the second crRNA may be located on the same plasmid or on different plasmids.
[0014] Furthermore, the regulatory factor LsrR is linked to the inducible promoter P lsrA The regulated defective nuclease can be located on the same plasmid, on a different plasmid, or directly integrated into the genome.
[0015] Furthermore, a WBJ sequence is inserted upstream of the 2′-fucosyllactose synthesis-related gene, and the first crRNA targets the WBJ sequence.
[0016] Furthermore, the nucleotide sequence of the WBJ sequence is shown in SEQ ID NO. 1. In an embodiment of the present invention, the WBJ sequence is composed of P tac The promoter regulates expression, and the nucleotide sequence is shown in SEQ ID NO.2.
[0017] Furthermore, the nucleotide sequence of the first crRNA is shown in SEQ ID NO.3.
[0018] Furthermore, the nucleotide sequence of the second crRNA is shown in SEQ ID NO.4.
[0019] Furthermore, the nucleotide sequence of the regulatory factor LsrR is shown in SEQ ID NO.5.
[0020] Furthermore, the nucleotide sequence of the defective nuclease dCas12a is shown in SEQ ID NO.6.
[0021] Furthermore, the first crRNA or the second crRNA is composed of P J23119 Promoter-regulated expression.
[0022] Furthermore, the P J23119 The nucleotide sequence of the promoter is shown in SEQ ID NO.7.
[0023] Furthermore, the regulatory factor LsrR is composed of P J23100 Promoter-regulated expression.
[0024] Furthermore, the P J23100 The nucleotide sequence of the promoter is shown in SEQ ID NO.8.
[0025] The second object of the present invention is to provide the use of the multi-layer dynamic control system in the preparation of 2′-fucosyllactose or products containing 2′-fucosyllactose.
[0026] The third object of the present invention is to provide a recombinant Escherichia coli containing the above-mentioned multi-layer dynamic regulatory system.
[0027] Furthermore, the starting strain was E. coli MG30. This starting strain is described in the Chinese patent application number CN202210269476.X. The specific construction method is as follows:
[0028] Using E. coli MG27 as the starting strain, the gene encoding EIICB was knocked out. Glc The enzyme gene ptsG, overexpressed the lactose permease gene lacY, and heterologously expressed the GDP-polyphosphate transferase gene ppk2 and the guanosine inosine kinase gene gsk.
[0029] Furthermore, the aforementioned genes were integrated into the genome for heterologous expression or overexpression, with the lacY gene integrated into the treB locus and the expression cassette consisting of the ppk2 and gsk genes integrated into the nupG locus. The ptsG gene is numbered as 945651; the lactose permease gene lacY is numbered as 949083; the GDP-polyphosphate transferase gene ppk2 is numbered as 879494; and the guanosine inosine kinase gene gsk is numbered as 946584.
[0030] Furthermore, the gene lacY is derived from P tac The promoter regulates expression; the gene ppk2 is expressed by P tac The promoter regulates expression; the gene gsk is expressed by PJ23119 Promoter-regulated expression.
[0031] Furthermore, E. coli MG27 is described in Chinese patent application number CN202011240682.5, where it is named MG-26ΔyjiP::trxA-futC. The specific construction method is as follows:
[0032] Using Escherichia coli MG1655△fliR::futC,△fuck::fkp,△lacI,△wcaJ,△lacZ,△flgA::futC,△flgG::futC as the host strain, the α-1,2-fucosyltransferase FutC with N-terminal fusion protein tag thioredoxin A (TrxA) was integrated into the yjip site.
[0033] Furthermore, the amino acid sequence of thioredoxin A is shown in SEQ ID NO.10, and the amino acid sequence of α-1,2-fucosyltransferase is shown in SEQ ID NO.11.
[0034] A fourth object of the present invention is to provide a method for constructing the above-mentioned recombinant Escherichia coli, comprising the following steps:
[0035] Insert the WBJ sequence upstream of the gene to be upregulated, and then insert the first crRNA, the second crRNA particle, the regulatory factor LsrR, the inducible promoter P lsrA and the defective nuclease dCas12a are introduced into the starting strain to construct the recombinant Escherichia coli.
[0036] Specifically, the genetically engineered strain of the present invention is based on Escherichia coli MG30 and the dCas12a-CRP expression plasmid pACYDuet-P J23100 -lsrR-P lsrA -dCas12a-CRP and crRNA expression plasmid pETDuet-P J23119 -crpfkA4、pETDuet-P J23119 -crWBJ2 and pETDuet-P J23119 -crpfkAs-crWBJ2 obtained.
[0037] The fifth object of the present invention is to provide a method for producing 2′-fucosyllactose, which uses the recombinant Escherichia coli for fermentation production.
[0038] The sixth object of the present invention is to provide a multi-gene crRNA array expression plasmid for increasing the production of 2′-fucosyllactose, the plasmid containing the nucleotide sequence shown in SEQ ID NO.3-4.
[0039] The seventh object of the present invention is to provide an Escherichia coli containing the above-mentioned multi-gene crRNA array expression plasmid, wherein the Escherichia coli inserts a nucleotide sequence such as the WBJ sequence shown in SEQ ID NO.1 upstream of the phosphomannoase genes manB and rcsA.
[0040] The eighth object of the present invention is to provide the use of the above-mentioned multi-gene crRNA array expression plasmid or Escherichia coli containing the plasmid in the preparation of 2′-fucosyllactose or a product containing 2′-fucosyllactose.
[0041] Beneficial effects of the present invention:
[0042] In order to test the inhibitory effect of the 3D circuit involved in the present invention on genes, 6 guide crRNAs targeting pfkA were designed to downregulate the central carbon metabolism pathway gene pfkA, and the effect of the 3D circuit on the de novo synthesis of 2'-FL was investigated. The results showed that targeting and inhibiting different positions of pfkA by different crpfkAs promoted the synthesis of 2'-FL. Among them, the use of crpfkA4 can effectively improve the synthesis of 2'-FL, and the yield of 2'-FL in shake flask fermentation was significantly increased from 9.1g / L to 16.6g / L. In addition, when the 3D circuit was used to activate the manB and rcsA genes, the yield of 2'-FL increased from 9.1g / L to 13.3g / L and 15.3g / L. Therefore, in order to further investigate the effect of simultaneous inhibition and activation of gene expression on the de novo synthesis of 2'-FL, the guide crRNA sequences crpfkA4 and crWBJ2 were assembled to construct the multi-gene targeted crRNA expression plasmid pETDuet-P J23119 -crpfkA4-crWBJ2, and fused with dCas12a-CRP protein expression plasmid pACYDuet-P J23100 -lsrR-P lsrA -dCas12a-CRP was co-transformed into MG30. The results showed that when the 3D circuit was used to simultaneously inhibit pfkA and activate manB and rcsA, the yield of 2'-FL de novo synthesis could be further increased to 18.4 g / L. This shows that the 3D circuit can be used to effectively promote 2'-FL synthesis and rationally coordinate the metabolic flows of the central carbon metabolism pathway and the product synthesis pathway. The construction method of the Escherichia coli genetically engineered strain of the present invention is simple and has good application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0043] Figure 1 shows the fluorescence inhibition effect of six different targeting-guided crpfkAs on the fusion protein pfkA-mCherry and their effects on the synthesis of 2'-FL;
[0044] Figure 2 shows the activation effect of different targeting-guided crWBJs on the fluorescent protein gene gfp;
[0045] FIG3 is an RT-qPCR analysis of the 3D circuit for dynamically regulating the transcriptional expression levels of genes in the de novo synthesis pathway;
[0046] Figure 4 shows the differences in the effects of starting bacteria, using a 3D circuit to activate manB and rcsA separately, and simultaneously activating manB to activate rcsA and inhibit the expression of pfkA on de novo 2'-FL synthesis;
[0047] FIG5 is a graph showing the results of 2′-FL synthesis by the 3Dia strain in a 3-L fermenter in fed-batch fermentation in Example 1 of the present invention. DETAILED DESCRIPTION
[0048] The present invention will be further described below with reference to the accompanying drawings and specific embodiments so that those skilled in the art can better understand the present invention and implement it. However, the embodiments are not intended to limit the present invention.
[0049] The scheme that the present invention relates to is as follows:
[0050] The present invention provides a dynamic regulatory strategy for downregulating the central carbon metabolism pathway gene pfkA in response to cell growth, and upregulating the expression levels of genes manB, manC, gmd, fcl, and rcsA in the 2'-FL de novo synthesis pathway, so as to dynamically coordinate the metabolic flow of cell growth and product synthesis, thereby effectively improving the efficiency of 2'-FL de novo synthesis.
[0051] On the one hand, to verify that the 3D loop can inhibit the expression of pfkA, mCherry was fused to the C-terminus of pfkA to construct the reporter protein plasmid pRSFDuet-P tac -pfkA-mCherry. Then six guide crRNAs plasmids were randomly designed on the pfkA gene coding frame. Then the reporter protein plasmid pRSFDuet-P tac -pfkA-mCherry, crRNA expression plasmid pETDuet-P J23119 -crpfkAs and dCas12a-CRP expression plasmid pACYDuet-P J23100 -lsrR-P lsrA -dCas12a-CRP was co-transformed into the MG1655:ΔlsrG strain, and crRNA without a targeting sequence was used as a control group to investigate the inhibitory effect of the 3D circuit on the gene.
[0052] Furthermore, to verify the activation effect of the 3D circuit on the target gene, the P tacThe WBJ regulatory element (SEQ ID NO.2) was integrated into each target gene manB, manC, gmd, fcl, rcsA, respectively, so as to form an RNA-protein complex with CRISPR protein using crWBJ2 guide sequence (SEQ ID NO.3) and recruit dCas12a-CRP activator to regulate gene expression. J23100 -lsrR-P lsrA -dCas12a-CRP and pETDuet-P J23119 -crWBJ2 were co-transformed into Escherichia coli to verify the relative transcription level of the target gene.
[0053] In a second aspect, the present invention further provides a metabolic regulation method for de novo synthesis of 2'-FL based on a multi-layer dynamic dual regulation strategy, the construction method comprising the following steps:
[0054] (1) 3D circuits dynamically inhibit central carbon metabolism pathways
[0055] mCherry was fused to the C-terminus of pfkA using (GGGGS)2 flexible linker to construct the reporter protein plasmid pRSFDuet-P tac -pfkA-mCherry. Six guide crRNAs plasmids were then randomly designed on the pfkA coding frame to construct the plasmid pETDuet-P J23119 -crpfkA1,pETDuet-P J23119 -crpfkA2,pETDuet-P J23119 -crpfkA3,pETDuet-P J23119 -crpfkA4,pETDuet-P J23119 -crpfkA5 and pETDuet-P J23119 -crpfkA6. Then the reporter protein plasmid pRSFDuet-P tac -pfkA-mCherry, crRNA expression plasmid pETDuet-P J23119 -crpfkAs and dCas12a-CRP expression plasmid pACYDuet-P J23100 -lsrR-P lsrA -dCas12a-CRP was co-transformed into the QS2 strain, and crRNA without targeting sequence was used as a control group. Subsequently, the bacterial OD was measured by a Cytation microplate reader (Cytation 3; BioTek, Winooski, USA). 600Finally, the crRNA expression plasmid pETDuet-P J23119 -crpfkAs and dCas12a-CRP expression plasmid pACYDuet-P J23100 -lsrR-P lsrA -dCas12a-CRP was co-transformed into the MG30 strain to investigate the effect of the 3D loop on the de novo synthesis of 2'-FL.
[0056] (2) 3D loop dynamically activates the GDP-L-fucose de novo synthesis pathway
[0057] In order to integrate the WBJ sequence and LsrR-QS regulatory sequence frame gene into each activation target site, the CHOPCHOP website (http: / / chopchop.cbu.uib.no / ) was used to design the sgRNA guide plasmid pTarget for each target. The CRISPR-Cas9 system was used to construct a promoter P on the genome. tac The WBJ sequence and LsrR-QS regulatory sequence frame were constructed, and kanamycin (Kanr) and spectinomycin (Specr) were used as colony screening markers. First, the P-terminal fragments were inserted before the genes manB, manC, gmd, fcl, and rcsA by fusion PCR. tac The regulatory element frame of the WBJ sequence and the knock-in gene with the LsrR-QS regulatory element P J23100 -lsrR-P lsrA The target gene's guide sgRNA plasmid was then designed, and the fusion PCR fragment and the pTarget plasmid for each site were electroporated into MG30 competent cells. Colony PCR and sequencing were then used to verify the integration of the fragment.
[0058] (3) Constructing a multi-gene crRNA array to simultaneously up-regulate and down-regulate gene expression and improve the efficiency of 2'-FL de novo synthesis
[0059] According to the results of activating and inhibiting gene expression on 2'-FL de novo synthesis in (1) and (2), crpfkA4 and crWBJ2, which have the best inhibitory effect on pfkA, were assembled in series to construct the multi-gene crRNA plasmid pETDuet-P J23119 -crpfkA4-crWBJ2, and dCas12a-CRP expression plasmid pACYDuet-P J23100 -lsrR-P lsrA -dCas12a-CRP was co-transformed into the MG30 strain to investigate the effects of simultaneous inhibition and activation of gene expression on the de novo synthesis of 2'-FL.
[0060] In a third aspect, the present invention further provides the use of the engineered Escherichia coli for synthesizing 2'-FL, wherein the engineered Escherichia coli is used to ferment and produce 2'-FL.
[0061] The method of the present invention is as follows:
[0062] To determine the production of 2'-FL and the substrate lactose consumption by recombinant E. coli, a high-performance liquid chromatography (HPLC) system (Agilent Technologies 1260 Series) was used to measure the production of 2'-FL and lactose in the fermentation broth. The extracellular concentrations of 2'-FL and lactose in the fermentation supernatant were determined using a Rezex ROA organic acid column (Phenomenex, Torrance, CA, USA). The HPLC detector was a differential detector, and the mobile phase was 0.01N dilute H2SO4. The column temperature was set at 55°C, and the flow rate was set at 0.6 mL / min.
[0063] Example 1
[0064] (1) 3D circuits dynamically downregulate central carbon metabolism pathways
[0065] mCherry was fused to the C-terminus of pfkA using a (GGGGS)2 flexible linker to construct the reporter protein plasmid pRSFDuet-pfkA-mCherry. Subsequently, six guide crRNAs plasmids were designed on the template and non-template chains on the pfkA coding frame to construct the plasmid pETDuet-P J23119 -crpfkA1,pETDuet-P J23119 -crpfkA2,pETDuet-P J23119 -crpfkA3,pETDuet-P J23119 -crpfkA4,pETDuet-P J23119 -crpfkA5 and pETDuet-P J23119 -crpfkA6. Then the reporter protein plasmid pRSFDuet-pfkA-mCherry, crRNA expression plasmid pETDuet-P J23119 -crpfkAs and dCas12a-CRP expression plasmid pACYDuet-P J23100 -lsrR-P lsrA -dCas12a-CRP was co-transformed into the MG1655:ΔlsrG strain, and crRNA without a targeting sequence was used as a control group. Subsequently, the bacterial OD was measured by a Cytation microplate reader (Cytation 3; BioTek, Winooski, USA). 600As shown in Figure 1, the six different targeting guide crpfkAs all exhibited fluorescence inhibition on the pfkA-mCherry fusion protein. Among them, crpfkA6 and crpfkA1 showed the weakest and strongest inhibition, respectively, with fluorescence intensity reduced by 4.3% to 82.6% compared to the control. This indicates that the 3D circuit can inhibit the expression of pfkA, a key gene in the central carbon metabolism pathway, to varying degrees.
[0066] Finally, the crRNA expression plasmid pETDuet-P J23119 -crpfkA4 was electroporated into the pACYDuet-P plasmid carrying dCas12a-CRP expression J23100 -lsrR-P lsrA The genetically engineered strain 3Di4 was constructed by electroporation of Escherichia coli containing -dCas12a-CRP to investigate the effect of the 3D loop on the de novo synthesis of 2'-FL.
[0067] Preparation method of competent E. coli by electroporation:
[0068] First, pACYDuet-P J23100 -lsrR-P lsrA -dCas12a-CRP plasmid was transformed into E. coli MG30 competent cells, spread on 30 μg / mL chloramphenicol plates, cultured at 37°C for 12 h, picked single colonies on the plates, inoculated into fresh LB medium containing 30 μg / mL chloramphenicol, and cultured at 37°C and 220 rpm overnight; the overnight culture solution was transferred to a 250 mL conical flask containing 50 mL LB medium at a 1% inoculum volume, and the OD value of the bacteria was determined. 600 When the value reaches 0.6-0.7, ice bath the bacterial solution for 20 minutes and centrifuge at 5000r / min to collect the cells; wash the cells once with pre-cooled sterile water, pour out the supernatant, and suspend the cells with 500-600μL pre-cooled 10% glycerol to prepare the cell suspension with pACYDuet-P J23100 -lsrR-P lsrA -dCas12a-CRP plasmid was electroporated into E. coli MG30 competent cells for later use.
[0069] (2) 3D loop dynamically activates the 2'-FL de novo synthesis pathway
[0070] To investigate the gene activation effect of the 3D circuit, the position of the guide RNA in the WBJ sequence was changed to investigate the effect of the binding region of different crWBJs to dCas12a-CRP on GFP fluorescence intensity. The results showed that when the crWBJ2 sequence (SEQ ID NO. 3) located 50 bp upstream of the transcription start site was used, the GFP fluorescence intensity was the highest, which was 2.0 times that of the sequence without a guide crRNA (Figure 2).
[0071] The 3D loop was further used to regulate the de novo synthesis pathway of 2'-FL. First, the WBJ sequence and the LsrR-QS regulatory sequence frame gene were integrated into each activation target site manB and rcsA. The sgRNA guide plasmid pTarget for each target was designed on the CHOPCHOP website (http: / / chopchop.cbu.uib.no / ). The CRISPR-Cas9 system was used to construct a promoter P on the genome. tac The WBJ sequence and LsrR-QS regulatory sequence frame were used, and kanamycin and spectinomycin were used as colony selection markers. First, the P-terminal fragments were inserted before the genes manB and rcsA by fusion PCR. tac The regulatory element frame of the WBJ sequence and the knock-in gene with the LsrR-QS regulatory element P J23100 -lsrR-P lsrA The target gene’s guide sgRNA plasmid was then designed, and the fusion PCR fragment and the pTarget plasmid of each site were electroporated into MG30 competent cells. Then, colony PCR and sequencing were performed to verify whether the integrated fragment was knocked in. Subsequently, pETDuet-P was co-transformed into the strain that had eliminated pCas9 and pTarget plasmids. J23119 -crWBJ2 and pACYDuet-P J23100 -lsrR-P lsrA -dCas12a-CRP plasmids were used to construct genetically engineered strains 3Da1 and 3Da5, respectively, to verify the relative transcription levels of target genes and 2'-FL synthesis. RT-qPCR results showed that the transcription levels of the manB and rcsA genes were significantly increased, ranging from 3.5 to 9.3 times that of the control group (Figure 3), demonstrating that the 3D circuit can be used to dynamically activate the expression levels of genes in the de novo synthesis pathway.
[0072] For typing with P tac Preparation method of electroporation competent MG30 containing WBJ sequence regulatory element cassette:
[0073] First, pCas9 plasmid was transformed into E. coli MG30 competent cells, spread on 50 μg / mL kanamycin plates, cultured at 30°C for 12 h, picked single colonies on the plates, inoculated into fresh LB medium containing 50 μg / mL kanamycin, and cultured overnight at 30°C and 220 rpm. The overnight culture solution was transferred to a 250 mL conical flask containing 50 mL LB medium at a 1% inoculum volume, and the OD value of the bacteria was determined. 600 When the value reaches 0.2, add arabinose with a final concentration of 30-40 mmol / L to induce the pCas9 plasmid to express Red recombinase; continue to culture until OD 600 The p-value of the purified protein was 0.6-0.7, and then the bacterial solution was ice-bathed for 20 minutes and centrifuged at 5000 r / min to collect the bacteria; the cells were washed twice with pre-cooled sterile water, the supernatant was poured out, and the bacteria were suspended in 600-700 μL of pre-cooled 10% glycerol to prepare E. coli MG30 competent cells carrying the pCas9 plasmid for later use.
[0074] (3) Constructing a multi-gene crRNA array to simultaneously up-regulate and down-regulate gene expression and improve the efficiency of 2'-FL de novo synthesis
[0075] According to the results of de novo synthesis of 2'-FL for activation and inhibition of gene expression in (1) and (2), crpfkA4 and crWBJ2 were assembled in series (SEQ ID NO.9) to construct the multi-gene crRNA array plasmid pETDuet-P J23119 -crpfkA4-crWBJ2, and dCas12a-CRP expression plasmid pACYDuet-P J23100 -lsrR-P lsrA -dCas12a-CRP was co-transformed into the MG30 strain to construct strain 3Dia, and the effects of simultaneous inhibition and activation of gene expression on the de novo synthesis of 2'-FL were investigated.
[0076] (4) De novo synthesis of 2'-FL by genetically engineered strains in shake flask fermentation
[0077] Single colonies of the genetically engineered strains 3Di4, 3Da1, 3Da5, and 3Dia constructed above were inoculated into LB medium containing ampicillin (50 μg / mL) and chloramphenicol (30 μg / mL) at a final concentration and cultured for 8-10 h to serve as seed liquid for shake flask fermentation. The seed liquid was then inoculated at a 1% inoculum into a 250 mL Erlenmeyer flask containing 20 mL of fermentation medium (20 g / L glucose, 12 g / L tryptone, 24 g / L yeast extract, 12.54 g / L dipotassium hydrogen phosphate, and 2.31 g / L potassium dihydrogen phosphate), and lactose was added at a final concentration of 10 g / L. Fermentation was then performed in shake flasks at 30°C and 220 rpm for 60 h.
[0078] At the end of fermentation, high-performance liquid chromatography (HPLC) was used to determine the 2'-FL production in the fermentation supernatant and the residual lactose in the fermentation broth. First, 1-2 mL of the fermentation broth was centrifuged at 12,000 rpm for 15-20 minutes. The supernatant was then collected and the extracellular 2'-FL and lactose concentrations were determined by HPLC. The HPLC results for 2'-FL and lactose in the fermentation broth are shown in Figure 4. Finally, the extracellular 2'-FL production of the genetically engineered strains 3Di4, 3Da1, 3Da5, and 3Dia (in which the 3D circuit is used to activate manB and rcsA and inhibit pfkA expression) reached 16.6 g / L, 13.3 g / L, 15.3 g / L, and 18.4 g / L, respectively.
[0079] (5) Fermentation verification of 3Dia de novo synthesis of 2'-FL in a 3-L fermenter
[0080] Finally, the ability of strain 3Dia, modified based on the dynamic regulation of the 3D circuit, to synthesize 2'-FL was verified in a 3-L fermentor. The fermentation medium in the 3-L fermentor consisted of 12 g / L yeast extract, 18 g / L yeast peptone, 2.0 g / L citric acid, 2.0 g / L MgSO4·7H2O, 3.2 g / L (NH4)2SO4, and 7.5 g / L K2HPO4·3H2O. The fermentation temperature was 30°C, and the pH was controlled between 6.0 and 6.5 using ammonia and phosphoric acid solutions. The dissolved oxygen content was maintained at 40-50% during fermentation. As shown in Figure 5, after 100 hours of fermentation, the 2'-FL production increased to 102.3 g / L, and the lactose yield was 1.06 mol / mol.
[0081] The recombinant E. coli constructed in the above examples were all tested using high-performance liquid chromatography (HPLC) to detect the production of 2'-FL and the residual amount of lactose in the fermentation supernatant. The peak elution times of the 2'-FL standard and lactose were 7.2 min and 7.9 min, respectively, detected by a Rezex ROA organic acid column (Phenomenex, Torrance, CA, USA). Therefore, a standard curve for 2'-FL and lactose can be determined based on the peak areas corresponding to the peak elution times of the standards at different concentrations. Subsequently, the peak areas of 2'-FL and lactose in the fermentation supernatant were detected, and finally, the extracellular production of 2'-FL and the residual amount of lactose were calculated using the standard curve. The HPLC detector was a differential detector, the mobile phase was eluted with 0.01N dilute H2SO4, the detection temperature of the chromatographic column was set to 55°C, and the detection flow rate was 0.6 mL / min.
[0082] Obviously, the above embodiments are merely examples for clarity of explanation and are not intended to limit the implementation methods. Those skilled in the art will appreciate that other variations or modifications can be made based on the above description. It is not necessary and impossible to enumerate all implementation methods here. Obvious variations or modifications arising therefrom remain within the scope of protection of the present invention.
Claims
1. A multi-layer dynamic control system for producing 2′-fucosyllactose, characterized in that: The multi-layer dynamic control system comprises: The constitutively expressed first crRNA targeting 2′-fucosyllactose synthesis-related genes, the constitutively expressed second crRNA targeting central carbon metabolism-related genes, the constitutively expressed regulatory factor LsrR, and the inducible promoter P lsrA regulated defective nuclease dCas12a; in, The multi-layer dynamic regulatory system upregulates the expression of genes related to 2′-fucosyllactose synthesis and downregulates the expression of genes related to central carbon metabolism; The 2′-fucosyllactose synthesis-related genes include one or more of the phosphomannoase genes manB, manC, gmd, fcl, and rcsA; The central carbon metabolism-related genes include the 6-phosphofructokinase gene pfkA.
2. The multi-layer dynamic control system according to claim 1, characterized in that: A WBJ sequence is inserted upstream of a gene related to 2′-fucosyllactose synthesis, and the first crRNA targets the WBJ sequence.
3. The multi-layer dynamic control system according to claim 2, characterized in that: The nucleotide sequence of the WBJ sequence is shown in SEQ ID NO.
1.
4. The multi-layer dynamic control system according to claim 2, characterized in that: The WBJ sequence consists of P tac Promoter regulates expression.
5. The multi-layer dynamic control system according to claim 1, characterized in that: The nucleotide sequence of the first crRNA is shown in SEQ ID NO.3; the nucleotide sequence of the second crRNA is shown in SEQ ID NO.
4.
6. The multi-layer dynamic control system according to claim 1, characterized in that: The nucleotide sequence of the regulatory factor lsrR is shown in SEQ ID NO.
5.
7. The multi-layer dynamic control system according to claim 1, characterized in that: The nucleotide sequence of the defective nuclease dCas12a is shown in SEQ ID NO.
6.
8. The multi-layer dynamic control system according to claim 1, characterized in that: The first crRNA or the second crRNA is composed of P J23119 Promoter regulates expression.
9. The multi-layer dynamic control system according to claim 1, characterized in that: The regulatory factor lsrR is composed of P J23100 Promoter regulates expression.
10. Use of the multi-layer dynamic control system according to any one of claims 1 to 9 in the preparation of 2'-fucosyllactose or a product containing 2'-fucosyllactose.
11. A recombinant Escherichia coli containing the multi-layer dynamic regulation system according to any one of claims 1 to 9.
12. The recombinant Escherichia coli according to claim 11, characterized in that: E. coli MG30 was used as the starting strain.
13. The recombinant Escherichia coli according to claim 12, characterized in that: The E. coli MG30 was based on the E. coli MG27 strain, in which the gene encoding EIICB was deleted. Glc The enzyme gene ptsG, overexpressed the lactose permease gene lacY, and heterologously expressed the GDP-polyphosphotransferase gene ppk2 and the guanosine inosine kinase gene gsk.
14. The recombinant Escherichia coli according to claim 13, characterized in that: The E. coli MG27 uses E. coli MG1655△fliR::futC,△fuck::fkp,△lacI,△wcaJ,△lacZ,△flgA::futC,△flgG::futC as a host bacterium and heterologously expresses α-1,2-fucosyltransferase with an N-terminal fusion protein tag.
15. The recombinant Escherichia coli according to claim 14, characterized in that: The protein tag is thioredoxin A.
16. The method for constructing a recombinant Escherichia coli according to any one of claims 11 to 15, characterized in that: The following steps are involved: The WBJ sequence was inserted upstream of the gene to be upregulated, and then the first crRNA, the second crRNA, the regulatory factor LsrR, the inducible promoter P lsrA and the defective nuclease dCas12a are introduced into the starting strain to construct the recombinant Escherichia coli.
17. A method for producing 2′-fucosyllactose, characterized in that: The recombinant Escherichia coli according to any one of claims 11 to 15 is used for fermentation production.
18. A multi-gene crRNA array expression plasmid for increasing 2′-fucosyllactose production, characterized in that: The plasmid contains the nucleotide sequence shown as SEQ ID NO.3-4.
19. An Escherichia coli containing the multi-gene crRNA array expression plasmid according to claim 18, characterized in that: The E. coli inserts the nucleotide sequence WBJ sequence shown in SEQ ID NO.1 upstream of the phosphomannoase gene manB and rcsA respectively.
20. Use of the multi-gene crRNA array expression plasmid according to claim 18 or the Escherichia coli containing the plasmid in the preparation of 2′-fucosyllactose or a product containing 2′-fucosyllactose.
Citation Information
Patent Citations
Base editing molecule and applications thereof
CN111454367A
Starting element based on AI-2 molecular response and Escherichia coli dynamic regulation and control system and method constructed by starting element
CN113667687A
Genetically engineered bacterium for producing fucosyllactose and production method
CN114480240A
Escherichia coli for synthesizing 2 '-fucosyllactose and construction method and application thereof
CN114672448A
Temperature-sensitive gene loop system as well as construction method and application thereof
CN114774419A
